Repurposing Licensed Drugs for Use Against Alzheimer's Disease

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2021 Apr 12

PMID 33843684

Citations 2

Authors

Leslie C Norins

Affiliations

Soon will be listed here.

Abstract

Substantial evidence, composed of drug mechanisms of action, in vivo testing, and epidemiological data, exists to support clinical testing of FDA-approved drugs for repurposing to the treatment of Alzheimer's disease (AD). Licensed compound investigation can often proceed at a faster and more cost-effective manner than un-approved compounds moving through the drug pipeline. As the prevalence of AD increases with life expectancy, the current rise in life expectancy amalgamated with the lack of an effective drug for the treatment of AD unnecessarily burdens our medical system and is an urgent public health concern. The unfounded reluctance to examine repurposing existing drugs for possible AD therapy further impedes the possibility of improving the quality of patient lives with a terminal disease. This review summarizes some evidence which exists to suggest certain already-approved drugs may be considered for the treatment of AD and will perhaps encourage physicians to off-label prescribe these safe therapeutics.

Citing Articles

Alzheimer's Disease: Exploring the Landscape of Cognitive Decline.

Tenchov R, Sasso J, Zhou Q ACS Chem Neurosci. 2024; 15(21):3800-3827.

PMID: 39392435 PMC: 11587518. DOI: 10.1021/acschemneuro.4c00339.

Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease.

Gong C, Dai C, Liu F, Iqbal K Front Aging Neurosci. 2022; 14:837649.

PMID: 35222001 PMC: 8864545. DOI: 10.3389/fnagi.2022.837649.

References

Daniels M, Rivers-Auty J, Schilling T, Spencer N, Watremez W, Fasolino V . Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun. 2016; 7:12504. PMC: 4987536. DOI: 10.1038/ncomms12504. View

Femminella G, Frangou E, Love S, Busza G, Holmes C, Ritchie C . Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019; 20(1):191. PMC: 6448216. DOI: 10.1186/s13063-019-3259-x. View

Ballard C, Corbett A, Sharp S . Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev Neurother. 2011; 11(3):327-9. DOI: 10.1586/ern.11.13. View

Craft S, Baker L, Montine T, Minoshima S, Watson G, Claxton A . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2011; 69(1):29-38. PMC: 3260944. DOI: 10.1001/archneurol.2011.233. View

Zhu X, Raina A, Rottkamp C, Aliev G, Perry G, Boux H . Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001; 76(2):435-41. DOI: 10.1046/j.1471-4159.2001.00046.x. View

Leyhe T, Eschweiler G, Stransky E, Gasser T, Annas P, Basun H . Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis. 2009; 16(3):649-56. DOI: 10.3233/JAD-2009-1004. View

Rivers-Auty J, Mather A, Peters R, Lawrence C, Brough D . Anti-inflammatories in Alzheimer's disease-potential therapy or spurious correlate?. Brain Commun. 2020; 2(2):fcaa109. PMC: 7585697. DOI: 10.1093/braincomms/fcaa109. View

Yulug B, Hanoglu L, Ozansoy M, Isik D, Kilic U, Kilic E . Therapeutic role of rifampicin in Alzheimer's disease. Psychiatry Clin Neurosci. 2018; 72(3):152-159. DOI: 10.1111/pcn.12637. View

Lahiri D . Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res. 1999; 26(3):137-46. DOI: 10.1111/j.1600-079x.1999.tb00575.x. View

10.

Gasparini L, Gouras G, Wang R, GROSS R, Beal M, Greengard P . Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001; 21(8):2561-70. PMC: 6762523. View

11.

Rosenbloom M, Barclay T, Pyle M, Owens B, Cagan A, Anderson C . A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs. 2014; 28(12):1185-9. DOI: 10.1007/s40263-014-0214-y. View

12.

Poeggeler B, Miravalle L, Zagorski M, Wisniewski T, Chyan Y, Zhang Y . Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001; 40(49):14995-5001. DOI: 10.1021/bi0114269. View

13.

Daulatzai M . "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging. Neurotox Res. 2015; 28(1):55-93. DOI: 10.1007/s12640-015-9528-x. View

14.

Anekonda T, Quinn J, Harris C, Frahler K, Wadsworth T, Woltjer R . L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis. 2010; 41(1):62-70. PMC: 2982927. DOI: 10.1016/j.nbd.2010.08.020. View

15.

Li L, Zhang Z, Holscher C, Gao C, Jiang Y, Liu Y . (Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur J Pharmacol. 2011; 674(2-3):280-6. DOI: 10.1016/j.ejphar.2011.11.005. View

16.

Song X, Xu A, Pan W, Wallin B, Kivlin R, Lu S . Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int J Mol Med. 2008; 22(1):9-16. View

17.

Loeb M, Molloy D, Smieja M, Standish T, Goldsmith C, Mahony J . A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004; 52(3):381-7. DOI: 10.1111/j.1532-5415.2004.52109.x. View

18.

Ugarte A, Gil-Bea F, Garcia-Barroso C, Cedazo-Minguez A, Ramirez M, Franco R . Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathol Appl Neurobiol. 2014; 41(4):471-82. DOI: 10.1111/nan.12203. View

19.

Ali T, Badshah H, Kim T, Kim M . Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. J Pineal Res. 2014; 58(1):71-85. DOI: 10.1111/jpi.12194. View

20.

Abuznait A, Cain C, Ingram D, Burk D, Kaddoumi A . Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol. 2011; 63(8):1111-8. PMC: 3163078. DOI: 10.1111/j.2042-7158.2011.01309.x. View